RT Journal Article
SR Electronic
T1 Prevalence and clinical importance of titin truncating variants in adults without known congestive heart failure
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 19005058
DO 10.1101/19005058
A1 James P. Pirruccello
A1 Alexander Bick
A1 Samuel Friedman
A1 Mark Chaffin
A1 Krishna G. Aragam
A1 Seung Hoan Choi
A1 Steven A. Lubitz
A1 Carolyn Y. Ho
A1 Kenney Ng
A1 Anthony Philippakis
A1 Patrick T. Ellinor
A1 Sekar Kathiresan
A1 Amit V. Khera
YR 2019
UL http://medrxiv.org/content/early/2019/08/20/19005058.abstract
AB Background Cross-sectional studies of various forms of dilated cardiomyopathy have noted a truncating mutation in the gene encoding titin (‘TTNtv’) in 7-30% of patients, but the clinical importance of identifying a TTNtv in an asymptomatic adult is largely unknown. In contrast to cross-sectional studies, prospective cohort studies allow for unbiased estimates of the disease risks associated with a genotype exposure.Objectives To determine the prevalence of cardiac imaging abnormalities and risk of incident disease among middle-aged TTNtv carriers without known congestive heart failure.Methods We analyze exome sequencing data of 45,747 participants of the UK Biobank without known congestive heart failure to identify TTNtv carriers. Among 10,552 with cardiac magnetic resonance imaging (MRI), we determine the relationship between TTNtv carrier status and left ventricular ejection fraction. In this prospective cohort, we quantify the absolute and relative risks of incident disease in TTNtv carriers versus noncarriers.Results Among 45,747 middle-aged participants without known congestive heart failure, 196 (0.43%) harbored a TTNtv. The average ejection fraction was 61% in TTNtv carriers versus 65% in noncarriers (P = 1.8 × 10−8), with a 9.3-fold increase (95% CI 3.9 – 22.2) in odds of subnormal ejection fraction (P = 5.7 × 10−5). Over a median follow-up of 6.9 years, a composite endpoint of incident dilated cardiomyopathy, congestive heart failure, or all-cause mortality was observed in 6.6% of TTNtv carriers versus 2.9% of non-carriers (adjusted hazard ratio 2.5; 95% CI 1.4 – 4.3; p = 1.1 × 10−3).Conclusions Approximately 1 in 230 middle-aged adults without known congestive heart failure harbored a TTNtv. These carriers had a substantially increased relative risk—but modest absolute risk—of having a subnormal ejection fraction or manifesting clinical disease during prospective follow-up.Condensed Abstract Cross-sectional studies of dilated cardiomyopathy have noted a truncating mutation in the gene encoding titin (‘TTNtv’) in up to 30% of patients—but the clinical importance of TTNtv in asymptomatic adults is largely unknown. Here, we observe a TTNtv in 0.43% of 45,747 middle-aged adults. Average ejection fraction was 61% in TTNtv carriers versus 65% in non-carriers (p<0.001). Over a median follow-up of 7 years, incident congestive heart failure or mortality was observed in 6.6% of TTTtv carriers versus 2.9% of non-carriers (hazard ratio 2.5; p = 0.001).Competing Interest StatementS.A.L. receives sponsored research support from Bristol Myers Squibb / Pfizer, Bayer AG, and Boehringer Ingelheim, and has consulted for Bristol Myers Squibb / Pfizer and Bayer AG. P.T.E. is supported by a grant from Bayer AG to the Broad Institute focused on the genetics and therapeutics of cardiovascular diseases, and has served on advisory boards or consulted for Bayer AG, Quest Diagnostics, and Novartis. S.K. is an employee of Verve Therapeutics, and holds equity in Verve Therapeutics, Maze Therapeutics, Catabasis, and San Therapeutics. He is a member of the scientific advisory boards for Regeneron Genetics Center and Corvidia Therapeutics; he has served as a consultant for Acceleron, Eli Lilly, Novartis, Merck, Novo Nordisk, Novo Ventures, Ionis, Alnylam, Aegerion, Haug Partners, Noble Insights, Leerink Partners, Bayer Healthcare, Illumina, Color Genomics, MedGenome, Quest, and Medscape; he reports patents related to a method of identifying and treating a person having a predisposition to or afflicted with cardiometabolic disease (20180010185) and a genetics risk predictor (20190017119). A.P. is a Venture Partner at GV, a subsidiary of Alphabet Corporation. A.V.K. has served as a consultant or received honoraria from Color Genomics, Illumina, and Navitor Pharmaceuticals, received grant support from the Novartis Institute for Biomedical Research and IBM Research, and reports a patent related to a genetic risk predictor (20190017119). The remaining authors have nothing to disclose.Funding StatementJ.P.P. is supported by the John S. LaDue Memorial Fellowship for Cardiovascular Research. K.G.A. is supported by the American Heart Association Institute for Precision Cardiovascular Medicine (17IFUNP33840012). S.A.L. is supported by NIH grant 1R01HL139731 and American Heart Association 18SFRN34250007. P.T.E. is supported by the Fondation Leducq (14CVD01), the NIH (1RO1HL092577, R01HL128914, K24HL105780) and the American Heart Association (18SFRN34110082). S.K. is supported by This work was funded by the the National Human Genome Research Institute of the US National Institutes of Health under award number 5UM1HG008895 (to S.K.), and the Ofer and Shelly Nemirovsky Research Scholar Award from Massachusetts General Hospital (to S.K.).A.V.K is supported by an institutional grant from the Broad Institute of MIT and Harvard (BroadIgnite), grant 1K08HG010155 from the National Human Genome Research Institute, a Hassenfeld Scholar Award from Massachusetts General Hospital, an institutional grant from the Broad Institute of MIT and Harvard (BroadNext10, to A.P. and S.K.), and a sponsored research agreement from IBM Research (to A.V.K., A.P., and S.K.).Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.Not ApplicableAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.Not ApplicableData is available to researchers from the UK Biobank following their standard access request procedures.MRImagnetic resonance imagingTTNtvtitin truncating variantsDCMdilated cardiomyopathyCHFcongestive heart failureCADcoronary artery diseaseLVEFleft ventricular ejection fractionLVEDVleft ventricular end diastolic volumeLVESVleft ventricular end systolic volumeICDInternational Statistical Classification of Diseases.